Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This study is a multi-center, phase II clinical trial, primarily enrolling patients with unresectable, locally advanced or metastatic undifferentiated thyroid cancer (ATC) or radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). Eligible patients will receive treatment with Sacituzumab tirumotecan combined with tislelizumab until disease progression or intolerability occurs. The effectiveness and safety will be evaluated.